Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerLisa A. Raedler
If approved, it will add to the drug’s recent approval for its use inbreast cancer in Europe, another first in the PARP inhibitor class, which also includesGSK/Tesaro’sZejula and Clovis’Rubraca. It will also help Lynparza maintain its growth, with EvaluatePharma forecasting it...
Lynparza is a PARP (poly ADP-ribose polymerase) inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a ...
a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is MMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin-blmf is internalized, followed by release
PARP inhibitorLynparza(olaparib) is a targeted treatment option that has been studied in HER2-negative early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to researchLyn...
Olapraib becomes the first PARP inhibitor to be approved for use in breast cancer."This class of drugs has been used to treat advanced BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer," commented Richard Pazdur...
Olaparib is a first-in-class PARP inhibitor with a broad and advanced clinical trial program across multiple GI tumor types including pancreatic and colorectal cancers. Olaparib is developed and commercialized in collaboration with Merck & ...
A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma Manon Durand, Vincent Cabaud Gibouin, Laurence Duplomb, Leila Salmi, Mélody Caillot, Brigitte Sola, Vincent Camus, Fabrice Jardin, Carmen Garri...
PARP inhibitor olaparib is a targeted treatment option that has been studied in HER2-negative early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with Merck & Co.,...
In vivo visualization of PARP inhibitor pharmacodynamics. JCI Insight. 2021;6(8): e146592. Article PubMed PubMed Central Google Scholar Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer ...